{"id":"W3006069344","doi":"10.1097/01.hs9.0000562576.71109.e9","title":"PS1071 PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST-IN-CLASS ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO-001, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Brentuximab vedotin; Vincristine; Prednisone; Internal medicine; CHOP; Cyclophosphamide; Lymphoma; Oncology; Clinical endpoint; CD30; Gastroenterology; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001162692,0.000989468,0.00111133,0.0003401503,0.0003057413,0.0007890182,0.0005695959,0.0008104985,0.003836806],"category_scores_gemma":[0.0009553041,0.0003590076,0.001086543,0.0003311751,0.0005904028,0.0006809313,0.0002518631,0.002881378,0.0009604663],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00083529,"about_ca_system_score_gemma":0.0009738809,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007775879,"about_ca_topic_score_gemma":0.001760498,"domain_scores_codex":[0.9996013,0.0002018749,0.00002403969,0.00005657692,0.00005044616,0.00006580097],"domain_scores_gemma":[0.9994554,0.0001718522,0.00008709824,0.00005351464,0.00004591059,0.0001863343],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3597615,0.07709023,0.009119204,0.001866502,0.003031786,0.00072959,0.0007177427,0.008370409,0.1396148,0.0007466354,0.01541234,0.3835392],"study_design_scores_gemma":[0.3487048,0.5903074,0.03089654,0.00007110856,0.001540064,0.0006634829,0.00009880244,0.002259783,0.01380036,0.0007640714,0.01084962,0.00004410661],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839166,0.004363412,0.001272584,0.001333014,0.000161036,0.001651866,0.001974851,0.0001729126,0.005153717],"genre_scores_gemma":[0.9850718,0.002787441,0.002199013,0.001399114,0.0001506004,0.00139825,0.003427098,0.00005940365,0.003507285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003836806,"threshold_uncertainty_score":0.01283538,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005682963985980265,"score_gpt":0.2428516738576754,"score_spread":0.2371687098716951,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}